Responses
Clinical/translational cancer immunotherapy
Original research
CLDN18.2 and 4-1BB bispecific antibody givastomig exerts antitumor activity through CLDN18.2-expressing tumor-directed T-cell activation
Compose a Response to This Article
Other responses
No responses have been published for this article.
